These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38447474)

  • 1. Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study.
    Bordet C; Zureik M; Zelmat Y; Lafaurie M; Lapeyre-Mestre M; Sommet A; Mazieres J; Despas F
    Cancer Treat Res Commun; 2024; 39():100801. PubMed ID: 38447474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
    Vaid AK; Gupta A; Momi G
    Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
    Farris M; Larkin-Kaiser KA; Scory T; Boyne D; Wilner KD; Pastel M; Cappelleri JC; Ivanova JI
    Future Oncol; 2020 Dec; 16(36):3107-3116. PubMed ID: 32869649
    [No Abstract]   [Full Text] [Related]  

  • 6. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
    Wang CC; Lai CH; Chang YP; Chang HC; Tseng CC; Huang KT; Lin MC
    Thorac Cancer; 2021 Dec; 12(23):3263-3272. PubMed ID: 34704378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
    Veerman GDM; Hurkmans DP; Paats MS; Oomen-de Hoop E; van der Leest CH; van Thiel ERE; Aerts JGJV; van Leeuwen RW; Dingemans AC; Mathijssen RHJ
    Biomed Pharmacother; 2022 Nov; 155():113695. PubMed ID: 36126454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
    Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ
    BMC Cancer; 2023 Feb; 23(1):151. PubMed ID: 36782147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
    Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
    Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.
    Sharma M; Holmes HM; Mehta HB; Chen H; Aparasu RR; Shih YT; Giordano SH; Johnson ML
    Cancer; 2019 Apr; 125(7):1155-1162. PubMed ID: 30605231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
    Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
    Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
    J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.
    Manninen O; Puuniemi L; Iivanainen S; Arffman M; Kaarteenaho R; Koivunen JP
    Acta Oncol; 2023 Dec; 62(12):1854-1861. PubMed ID: 37934101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N; Mera T; Märten A; Hochmair MJ
    Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.